Literature DB >> 15477405

Role of IKur in controlling action potential shape and contractility in the human atrium: influence of chronic atrial fibrillation.

Erich Wettwer1, Ottó Hála, Torsten Christ, Jürgen F Heubach, Dobromir Dobrev, Michael Knaut, András Varró, Ursula Ravens.   

Abstract

BACKGROUND: The ultrarapid outward current I(Kur) is a major repolarizing current in human atrium and a potential target for treating atrial arrhythmias. The effects of selective block of I(Kur) by low concentrations of 4-aminopyridine or the biphenyl derivative AVE 0118 were investigated on right atrial action potentials (APs) in trabeculae from patients in sinus rhythm (SR) or chronic atrial fibrillation (AF). METHODS AND
RESULTS: AP duration at 90% repolarization (APD90) was shorter in AF than in SR (300+/-16 ms, n=6, versus 414+/-10 ms, n=15), whereas APD20 was longer (35+/-9 ms in AF versus 5+/-2 ms in SR, P<0.05). 4-Aminopyridine (5 micromol/L) elevated the plateau to more positive potentials from -21+/-3 to -6+/-3 mV in SR and 0+/-3 to +12+/-3 mV in AF. 4-Aminopyridine reversibly shortened APD90 from 414+/-10 to 350+/-10 ms in SR but prolonged APD90 from 300+/-16 to 320+/-13 ms in AF. Similar results were obtained with AVE 0118 (6 micromol/L). Computer simulations of I(Kur) block in human atrial APs predicted secondary increases in I(Ca,L) and in the outward rectifiers I(Kr) and I(Ks), with smaller changes in AF than SR. The indirect increase in I(Ca,L) was supported by a positive inotropic effect of 4-aminopyridine without direct effects on I(Ca,L) in atrial but not ventricular preparations. In accordance with the model predictions, block of I(Kr) with E-4031 converted APD shortening effects of I(Kur) block in SR into AP prolongation.
CONCLUSIONS: Whether inhibition of I(Kur) prolongs or shortens APD depends on the disease status of the atria and is determined by the level of electrical remodeling.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15477405     DOI: 10.1161/01.CIR.0000145155.60288.71

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  100 in total

1.  Isoenzyme-specific regulation of cardiac Kv1.5/Kvβ1.2 ion channel complex by protein kinase C: central role of PKCβII.

Authors:  Fathima Fischer; Nadine Vonderlin; Claudia Seyler; Edgar Zitron; Sevil Korkmaz; Gábor Szabó; Dierk Thomas; Hugo A Katus; Eberhard P Scholz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-02-28       Impact factor: 3.000

Review 2.  New developments in atrial antiarrhythmic drug therapy.

Authors:  Alexander Burashnikov; Charles Antzelevitch
Journal:  Nat Rev Cardiol       Date:  2010-03       Impact factor: 32.419

3.  Atrial-selective sodium channel block strategy to suppress atrial fibrillation: ranolazine versus propafenone.

Authors:  Alexander Burashnikov; Luiz Belardinelli; Charles Antzelevitch
Journal:  J Pharmacol Exp Ther       Date:  2011-10-17       Impact factor: 4.030

Review 4.  [New antiarrhythmic drugs for therapy of atrial fibrillation: I. Ion channel blockers].

Authors:  U Ravens; E Wettwer; U Schotten; R Wessel; D Dobrev
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2006-06

Review 5.  Antiarrhythmic drugs 2013: state of the art.

Authors:  Kapil Kumar; Peter J Zimetbaum
Journal:  Curr Cardiol Rep       Date:  2013-10       Impact factor: 2.931

6.  Modeling the effect of Kv1.5 block on the canine action potential.

Authors:  Joachim Almquist; Mikael Wallman; Ingemar Jacobson; Mats Jirstrand
Journal:  Biophys J       Date:  2010-11-03       Impact factor: 4.033

Review 7.  Novel pharmacological targets for the rhythm control management of atrial fibrillation.

Authors:  Alexander Burashnikov; Charles Antzelevitch
Journal:  Pharmacol Ther       Date:  2011-08-17       Impact factor: 12.310

8.  Is there a functional correlate of Kv1.5 in the ventricle of canine heart and what would it mean for the use of I(Kur) blockers?

Authors:  E Wettwer
Journal:  Br J Pharmacol       Date:  2007-09-17       Impact factor: 8.739

Review 9.  Cardiac adrenergic control and atrial fibrillation.

Authors:  Antony J Workman
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-12-04       Impact factor: 3.000

Review 10.  Atrial Ca2+ signaling in atrial fibrillation as an antiarrhythmic drug target.

Authors:  Dobromir Dobrev
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-09-26       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.